A role for carbapenem in the treatment of melioidosis in developing countries?

摘要

Melioidosis, a disease caused by Burkholderia pseudomallei, is endemic to Southeast Asia and northern Australia. Patients with diabetes and chronic renal failure have a higher risk of contracting melioidosis. Therapeutic approaches are targeted at either the clinical resolution of acute infection (acute phase) or the eradication of residual intracellular infection to prevent relapse (maintenance phase). In Thailand, the first-line regimen in the acute phase is intravenous ceftazidime with or without trimethoprim-sulfamethoxazole (TMP-SMX).